KIT and mastocytosis: Besides inhibition of BCR-ABL, nilotinib has also shown in vitro activity against other kinases, particularly PDGFRα and KIT, which has led to the investigation of its potential clinical utility in diseases driven by these kinases such as gastrointestinal stromal tumors (GISTs) and mastocytosis.